Claudia Crimi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6744519/publications.pdf

Version: 2024-02-01

186209 289141 2,134 78 28 40 h-index citations g-index papers 82 82 82 2408 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomised controlled trial. Thorax, 2023, 78, 354-361.	2.7	38
2	Impact of asthma on bronchiectasis severity and risk of exacerbations. Journal of Asthma, 2022, 59, 469-475.	0.9	17
3	High-Flow Nasal Cannula and COVID-19: A Clinical Review. Respiratory Care, 2022, 67, 227-240.	0.8	51
4	Biologics in severe asthma. Minerva Medica, 2022, 113, .	0.3	15
5	Effectiveness of benralizumab in severe eosinophilic asthma: Distinct subâ€phenotypes of response identified by cluster analysis. Clinical and Experimental Allergy, 2022, 52, 312-323.	1.4	19
6	Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma. Expert Review of Respiratory Medicine, 2022, 16, 183-195.	1.0	5
7	Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer. Cancers, 2022, 14, 922.	1.7	5
8	Diastolic Function and Positive Airway Pressure: More Research Is Warranted. Respiration, 2022, , 1-3.	1.2	1
9	Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets. Frontiers in Pharmacology, 2022, 13, 851940.	1.6	41
10	A Key to Unlocking the Mysteries of COVID-19 Pulmonary Sequelae: Are We There?. Respiration, 2022, , 1-2.	1.2	O
11	Novel Biological Therapies for Severe Asthma Endotypes. Biomedicines, 2022, 10, 1064.	1.4	10
12	Ultrasoundâ€guided placement of Long Peripheral Cannula in children with Cystic Fibrosis Pediatric Pulmonology, 2022, , .	1.0	1
13	Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines, 2022, 10, 974.	2.1	7
14	Practical considerations for spirometry during the COVID-19 outbreak: Literature review and insights. Pulmonology, 2021, 27, 438-447.	1.0	47
15	COVIDâ€19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 887-892.	2.7	69
16	Challenges for the female health-care workers during the COVID-19 pandemic: the need for protection beyond the mask. Pulmonology, 2021, 27, 1-3.	1.0	9
17	REINVENT: ERS International survey on REstrictive thoracic diseases IN long term home noninvasive VENTilation. ERJ Open Research, 2021, 7, 00911-2020.	1.1	21
18	Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression. Journal of Asthma and Allergy, 2021, Volume 14, 163-173.	1.5	39

#	Article	IF	CITATIONS
19	Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVIDâ€19?. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 961-962.	2.7	3
20	Performance of EasyBreath Decathlon Snorkeling mask for delivering continuous positive airway pressure. Scientific Reports, 2021, 11, 5559.	1.6	8
21	Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma. International Journal of Molecular Sciences, 2021, 22, 4369.	1.8	33
22	Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program. Journal of Asthma and Allergy, 2021, Volume 14, 575-583.	1.5	36
23	Secretion management in patients with ineffective airway clearance with non-invasive mechanical ventilation use: Expert guidance for clinical practice. Monaldi Archives for Chest Disease, 2021, , .	0.3	3
24	Is the Power Spectrum of Electromyography Signal a Feasible Tool to Estimate Muscle Fiber Composition in Patients with COPD?. Journal of Clinical Medicine, 2021, 10, 3815.	1.0	13
25	Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study. Respiratory Medicine, 2021, 185, 106491.	1.3	33
26	Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4371-4380.e4.	2.0	37
27	High flow nasal therapy in Acute Exacerbation of COPD: Ready for the prime time?. American Journal of Emergency Medicine, 2021, 48, 331-332.	0.7	0
28	Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma. Biomedicines, 2021, 9, 1108.	1.4	24
29	Impact of chronic obstructive pulmonary disease on passive viscoelastic components of the musculoarticular system. Scientific Reports, 2021, 11, 18077.	1.6	8
30	Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis. Journal of Asthma and Allergy, 2021, Volume 14, 1165-1172.	1.5	31
31	Why, whether and how to use high-flow nasal therapy in acute exacerbations of chronic obstructive pulmonary disease. Journal of Comparative Effectiveness Research, 2021, 10, 1317-1321.	0.6	3
32	Type 2-High Severe Asthma with and without Bronchiectasis: A Prospective Observational Multicentre Study. Journal of Asthma and Allergy, 2021, Volume 14, 1441-1452.	1.5	21
33	Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy. Biomedicines, 2021, 9, 1822.	1.4	13
34	New treatments for asthma: From the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant. Pharmacological Research, 2020, 155, 104490.	3.1	20
35	Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. World Allergy Organization Journal, 2020, 13, 100462.	1.6	38
36	Molecular Targets for Biological Therapies of Severe Asthma. Frontiers in Immunology, 2020, 11, 603312.	2.2	65

#	Article	IF	Citations
37	Resumption of respiratory outpatient services in the COVID-19 era: Experience from Southern Italy. American Journal of Infection Control, 2020, 48, 1087-1089.	1.1	9
38	High flow nasal therapy versus noninvasive ventilation as initial ventilatory strategy in COPD exacerbation: a multicenter non-inferiority randomized trial. Critical Care, 2020, 24, 692.	2.5	61
39	Realâ€life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clinical and Experimental Allergy, 2020, 50, 780-788.	1.4	52
40	Comparability of asthma control test scores between self and physician-administered test. Respiratory Medicine, 2020, 170, 106015.	1.3	19
41	The Link between Asthma and Bronchiectasis: State of the Art. Respiration, 2020, 99, 463-476.	1.2	32
42	Adherence to omalizumab: A multicenter "real-world" study. World Allergy Organization Journal, 2020, 13, 100103.	1.6	20
43	Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma. SAGE Open Medical Case Reports, 2020, 8, 2050313X2090696.	0.2	17
44	Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomedicine and Pharmacotherapy, 2020, 129, 110444.	2.5	29
45	High Flow Nasal Therapy Use in Patients with Acute Exacerbation of COPD and Bronchiectasis: A Feasibility Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 184-190.	0.7	20
46	Clinical relevance of understanding mitogen-activated protein kinases involved in asthma. Expert Review of Respiratory Medicine, 2020, 14, 501-510.	1.0	20
47	Reliability and usefulness of a rapid IgMâ€IgG antibody test for the diagnosis of SARS-CoV-2 infection: A preliminary report Journal of Infection, 2020, 81, e53-e54.	1.7	45
48	Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use. F1000Research, 2020, 9, 637.	0.8	12
49	Noninvasive respiratory support in acute hypoxemic respiratory failure associated with COVID-19 and other viral infections. Minerva Anestesiologica, 2020, 86, 1190-1204.	0.6	37
50	Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use. F1000Research, 2020, 9, 637.	0.8	5
51	Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101830.	1.1	44
52	Prevalence and determinants of co-morbidities in patients with obstructive apnea and chronic obstructive pulmonary disease. European Journal of Internal Medicine, 2019, 69, e15-e16.	1.0	8
53	Long-Term Ventilation in Neuromuscular Patients: Review of Concerns, Beliefs, and Ethical Dilemmas. Respiration, 2019, 97, 185-196.	1.2	35
54	Effect of high-flow nasal therapy on dyspnea, comfort, and respiratory rate. Critical Care, 2019, 23, 201.	2.5	34

#	Article	IF	Citations
55	Shadow cost of oral corticosteroids-related adverse events: AÂpharmacoeconomic evaluation applied to real-life data fromÂtheÂSevereÂAsthma Network in Italy (SANI) registry. World Allergy Organization Journal, 2019, 12, 100007.	1.6	82
56	Noninvasive continuous arterial pressure monitoring with Clearsight during awake carotid endarterectomy. European Journal of Anaesthesiology, 2019, 36, 144-152.	0.7	16
57	High flow nasal therapy in immunocompromised patients with acute respiratory failure: A systematic review and meta-analysis. Journal of Critical Care, 2019, 50, 250-256.	1.0	32
58	Bronchiectasis and asthma: a dangerous liaison?. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 46-52.	1.1	34
59	State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. European Respiratory Review, 2018, 27, 170139.	3.0	47
60	Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients. International Journal of COPD, 2018, Volume 13, 3131-3139.	0.9	50
61	Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD. Monaldi Archives for Chest Disease, 2018, 88, 886.	0.3	17
62	Remifentanil-induced postoperative hyperalgesia: current perspectives on mechanisms and therapeutic strategies. Local and Regional Anesthesia, 2018, Volume 11, 15-23.	2.8	73
63	Misdiagnosis of asthma and COPD and underuse of spirometry in primary care unselected patients. Respiratory Medicine, 2018, 142, 48-52.	1.3	81
64	Exhaled breath condensate pH and cysteinyl leukotriens in patients with chronic cough secondary to acid gastroesophageal reflux. Journal of Breath Research, 2017, 11, 016002.	1.5	3
65	The accuracy of the HemoCue <scp>WBC DIFF</scp> in assessing blood eosinophils depends on the clinical setting and medical condition. Acta Paediatrica, International Journal of Paediatrics, 2017, 106, 1706-1706.	0.7	2
66	Point-of-care blood eosinophil count in a severe asthma clinic setting. Annals of Allergy, Asthma and Immunology, 2017, 119, 16-20.	0.5	26
67	Domiciliary Non-invasive Ventilation in COPD: An International Survey of Indications and Practices. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 483-490.	0.7	72
68	Bronchodilator response as a marker of poor asthma control. Respiratory Medicine, 2016, 112, 45-50.	1.3	33
69	Epidemiology, Practice and New Trends in Noninvasive Mechanical Ventilation: What Are We Learning?. , 2016, , 829-838.		0
70	Fully Covered Self-Expandable Metal Stent in Tracheobronchial Disorders: Clinical Experience. Respiration, 2015, 89, 49-56.	1.2	38
71	Short-term variability in respiratory impedance and effect of deep breath in asthmatic and healthy subjects with airway smooth muscle activation and unloading. Journal of Applied Physiology, 2013, 115, 708-715.	1.2	16
72	Prolonged respiratory failure. Critical Care Medicine, 2012, 40, 2505-2506.	0.4	1

#	Article	IF	CITATION
73	Acute additive effect of montelukast and beclomethasone on AMP induced bronchoconstriction. Respiratory Medicine, 2010, 104, 1417-1424.	1.3	4
74	Airway hyperresponsiveness with chest strapping: A matter of heterogeneity or reduced lung volume?. Respiratory Physiology and Neurobiology, 2009, 166, 47-53.	0.7	14
75	Fatal Heparin-Induced Thrombocytopenia 8 Months After Prior Exposure to Heparin. Journal of Cardiothoracic and Vascular Anesthesia, 2008, 22, 732-734.	0.6	1
76	Determinants of tracheostomy decannulation: an international survey. Critical Care, 2008, 12, R26.	2.5	118
77	Effect of laboratory testing guidelines on the utilization of tests and order entries in a surgical intensive care unit*. Critical Care Medicine, 2008, 36, 2993-2999.	0.4	69
78	Interaction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells. Respiratory Research, 2005, 6, 103.	1.4	19